Received: 28 March 2020
Accepted: 27 May 2020
First Online: 12 June 2020
Ethics approval and consent to participate
: Patient data used in this study was anonymized prior to use for research purposes. All subjects consented to the App M-sense’s terms of service and data protection declaration that abides by the General Data Protection Regulation (GDPR). Further, the study has been approved by Charité – Universitätsmedizin Berlin’s institutional ethics committee (project number: EA2/232/18).
: Not applicable.
: AR was employed at Newsenselab GmbH (App M-sense) as an intern prior to his research at the Institute of Public Health Berlin until September 2017.MD is a Co-founder and shareholder of the Newsenselab GmbH.TK reports having contributed to an advisory board of CoLucid and a research project funded by Amgen, for which the Charité – Universitätsmedizin Berlin received an unrestricted compensation. He further reports having received honoraria from Lilly, Newsenselab, and Total for providing methodological advice, from Novartis and from Daiichi Sankyo for providing a lecture on neuroepidemiology and research methods, and from the BMJ for editorial services.LN contributed to advisory boards of Hormosan, Lilly and Novartis. He received speaking fees from Allergan, Biogen, Hormosan, Lilly, Novartis and TEVA.